BioNTech Shares Are Trading Lower After the FDA Placed a Clinical Hold on Partner Medilink Therapeutics' Phase 1 Trial of BNT326/YL202.
BioNTech Shares Are Trading Lower After the FDA Placed a Clinical Hold on Partner Medilink Therapeutics' Phase 1 Trial of BNT326/YL202.
biontech股份下跌，原因是美國FDA對合作夥伴medilink therapeutics的BNT326/YL202一期臨床試驗發佈了臨床暫停令。
BioNTech Shares Are Trading Lower After the FDA Placed a Clinical Hold on Partner Medilink Therapeutics' Phase 1 Trial of BNT326/YL202.
biontech股份下跌，原因是美國FDA對合作夥伴medilink therapeutics的BNT326/YL202一期臨床試驗發佈了臨床暫停令。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。